Article
Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype.
PloS one - 1 Jan 2012
Schurgers Leon J, Joosen Ivo A, Laufer Eduard M, Chatrou Martijn L L, Herfs Marjolein, Winkens Mark H M, Westenfeld Ralf, Veulemans Verena, Krueger Thilo, Shanahan Catherine M, Jahnen-Dechent Willi, Biessen Erik, Narula Jagat, Vermeer Cees, Hofstra Leonard, Reutelingsperger Chris P
Abstract excerpt
BACKGROUND: Vitamin K-antagonists (VKA) are treatment of choice and standard care for patients with venous thrombosis and thromboembolic risk. In experimental animal models as well as humans, VKA have been shown to promote medial elastocalcinosis. As vascular calcification is considered an independent risk factor for plaque instability, we here investigated the effect of VKA on coronary calcification in patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.